The purpose of this non-interventional study is to collect data on the efficiency and safety of pomalidomide in combination with dexamethasone in the routine application

Inclusion Criteria:

• Patients with relapsed or refractory multiple myeloma Patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
• Adult male and female patients (at least 18 years with no upper age limit)
• Written informed consent to data collection and pseudonymized data transfer
• The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics Imnovid®)
• Other criteria according to summary of product characteristics Imnovid®

Exclusion Criteria:

• Missing patient's informed consent
• Pregnant or breast-feeding women
• Male patients, not capable of complying the required preventive measures (see summary of product characteristics Imnovid®)
• Other criteria according to summary of product characteristics Imnovid®

Adult patients with relapsing or refractory multiple myeloma previously treated with at least two prior lines of therapy, including bortezomib and lenalidomide who have progressed under their last therapy regimen